# US 2026/0168000 A1 · Genetically modified benzylisoquinoline alkaloid-producing host cells with modified efflux transporter gene expression

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0168000 A1
- Document ID: US20260168000A1
- Status: Published application
- Kind: A1
- Application number: 19/127,269
- Filed: 2023-11-07
- Published: 2026-06-18
- Earliest claimed: 2022-11-08
- Assignees: River Stone Biotech Aps
- Applicants: River Stone Biotech Aps
- Inventors: Esben Halkjaer HANSEN; Laura Tatjer RECORDA; Pernille Lund LYNEBORG; Giedre BACINSKAJA; Jens HOUGHTON-LARSEN
- Web page: https://patentgrep.com/patent/US20260168000A1

## CPC

- C12P 17/188: {Heterocyclic compound containing in the condensed system at least one hetero ring having nitrogen atoms and oxygen atoms as the only ring heteroatoms (ergot-alcaloids C12P17/183)}
- C07K 14/395: from Saccharomyces
- C12N 1/18: Baker's yeast; Brewer's yeast
- C12N 9/0042: {NADPH-cytochrome P450 reductase (1.6.2.4)}
- C12N 9/0071: {acting on paired donors with incorporation of molecular oxygen (1.14)}
- C12N 9/2445: {Beta-glucosidase (3.2.1.21)}
- C12N 15/52: Genes encoding for enzymes or proenzymes
- C12P 19/60: having an oxygen of the saccharide radical directly bound to a non-saccharide heterocyclic ring or a condensed ring system containing a non-saccharide heterocyclic ring, e.g. coumermycin, novobiocin {(C12P19/605)}
- C07K 2319/03: containing a transmembrane segment
- C12R 2001/865: Saccharomyces cerevisiae
- C12Y 106/02004: NADPH-hemoprotein reductase (1.6.2.4), i.e. NADP-cytochrome P450-reductase
- C12Y 114/14001: Unspecific monooxygenase (1.14.14.1)
- C12Y 302/01021: Beta-glucosidase (3.2.1.21)
- C12P: FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE {(brewing of beer C12C; producing vinegar C12J; producing specific peptides or proteins C07K; producing enzymes C12N9/00; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; measuring or testing processes involving enzymes or microorganisms C12Q; measuring or testing processes involving nucleic acid amplification reactions C12Q1/6844; fermentation processes to form a food composition, A21 or A23; compounds in general, see the relevant compound class, e.g. C01, C07)}
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12R: INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12Y: ENZYMES

## Abstract

The invention relates to genetically modified hosts cell comprising a recombinant pathway having enhanced production of one or more benzylisoquinoline alkaloids or glycosylated benzylisoquinoline alkaloid, wherein the host cell has been further modified so as to have an increased ability to export end products of the recombinant pathway (such as nororipavine or gly-nororipavine).

## Claims

### Claim 1

A recombinant microbial host cell capable of producing one or more BIA, BIA-glycoside, oripavine or glycosylated oripavine or glucosylated oripavine, thebaine, northebaine, nororipavine, glycosylated nororipavine or glucosylated nororipavine, wherein the host cell comprises a recombinant polynucleotide comprising a promoter operably linked to an ABC transporter effluxing one or more BIA or BIA-glycoside products.

### Claim 2 (depends on 1)

The recombinant microbial host cell of claim 1, wherein one or more of the ABC transporters are one or more selected from:
a. present in the host cell at a gene copy number greater than in the wild type of the microbial host cell,
b. operably linked to a constitutive promoter or an inducible promoter that induces expression during cell exponential phase and BIA production, or
c. are under regulatory control such that a higher level of gene expression is induced by growth medium, growth conditions, the presence of an activator or transcription factor or absence of a repressor for an inducible promoter governing expression of the one or more endogenous ABC transporters, or any combination thereof.

### Claim 3 (depends on 1, 2)

The recombinant microbial host cell of claim 1 or 2, wherein the increased expression of one or more endogenous ABC transporters results from elevated levels of one or more transcription factors, wherein the one or more transcription factors are selected from:
a. polypeptide sequence having at least 75%, such as at least 80%, such as at least 85%, such as at least 90%, such as at least 95%, such as at least 99%, or 100% identity to SEQ ID No. 902, 904, 906, 908, or
b. encoded by a nucleic acid sequence having at least 75%, such as at least 80%, such as at least 85%, such as at least 90%, such as at least 95%, such as at least 99%, or 100% identity to SEQ ID No. 901, 903, 905, 907, or genomic DNA thereof.

### Claim 4

The recombinant microbial host cell of any preceding claim, wherein the transcription factor is PDR 1, PDR3, PDR8 and/or YRR1.

### Claim 5

A recombinant microbial host cell according to any preceding claim, wherein the recombinant microbial host cell excretes the BIA, BIA-glycoside, oripavine, glycosylated oripavine or glucosylated oripavine, thebaine, northebaine, nororipavine, glycosylated nororipavine or glucosylated nororipavine produced by the recombinant microbial host cell, at greater than 2%, preferably greater than 5%, preferably greater than 10%, preferably greater than 20% more excretion compared to a negative control recombinant microbial host cell not expressing the ABC transporter during cell exponential phase and BIA production.

### Claim 6

A recombinant microbial host cell according to any preceding claim, wherein the recombinant microbial host cell produces the one or more of the BIAs at greater than 2%, preferably more than 5%, preferably more than 10%, preferably more than 20%, preferably more than 50% more than a negative control recombinant microbial host cell not expressing the ABC transporter during cell exponential phase and BIA production.

### Claim 7

A recombinant microbial host cell according to any preceding claim, wherein the one or more excreted BIAs are thebaine, nororipavine, oripavine, glucosylated oripavine or glucosylated nororipavine.

### Claim 8

The recombinant microbial host cell of any preceeding claim, wherein the ABC transporter is an ABC transporter involved in drug efflux or xenobiotic efflux.

### Claim 9

The recombinant microbial host cell of any preceeding claim, wherein the ABC transporter comprises a Walker A sequence G(A/S/R)(S/T)GAGK(S/T), a linker sequence (L/V)SGG(E/Q), and a Walker B sequence comprising four hydrophobic residues, an optional additional fifth hydrophobic residue and a D such that (I/L)(I/L)(I/V/L)(F/L/M)XD where X represents the optional additional hydrophobic residue or no additional residue.

### Claim 10

The recombinant microbial host cell of any preceding claim, wherein the ABC transporter is:
a. an ABCC/multi-drug resistance associated protein (MRP) ABC transporters, or
b. an ABCG/pleiotropic drug resistance (PDR) ABC transporters.

### Claim 11

The recombinant microbial host cell of any preceding claim, wherein the ABC transporter is not native to a BIA-producing plant.

### Claim 12

The recombinant microbial host cell of any preceding claim, wherein the ABCC/multi-drug resistance associated protein (MRP) ABC transporter is:
a. a polypeptide comprising a sequence having at least 45%, such as at least 60%, such as at least 70%, such as at least 80%, such as at least 85%, such as at least 90%, such as at least 95%, such as at least 99%, such as 100% identity to SEQ ID No. 872, 910, 912, 914, 918, 920, 922, 924, 926, 928, 930, 932, 934, 936, 938, 940, 942, 956, 960, 962, 964, 966, 970, 1032, 1034, 1038 or 1040 or
b. encoded by a nucleic acid sequence having at least 45%, such as at least 60%, such as at least 70%, such as at least 80%, such as at least 85%, such as at least 90%, such as at least 95%, such as at least 99%, such as 100% identity to SEQ ID No. 871, 909, 911, 913, 917, 919, 921, 923, 925, 927, 929, 931, 933, 935, 937, 939, 941, 955, 959, 961, 963, 965, 969, 1031, 1033, 1037 or 1039 or genomic DNA thereof.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The recombinant microbial host cell of any of claims 1 to 11, wherein the ABC transporter comprises Walker A sequences G(X)(I/V)G(S/T)GK where X is a residue selected from P, L, S, A, V or M and GRTGAGK, two linker sequences comprising LSGGQ and NFSLGE, and Walker B sequences (I/V/T)(I/Y/V)L(M/F/L)D and I(I/L)(I/V)(L/M)D.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The recombinant microbial host cell of any of claims 1 to 11, wherein the ABCG/pleiotropic drug resistance (PDR) ABC transporter is:
a. a polypeptide comprising a sequence having at least 45%, such as at least 60%, such as at least 75%, such as at least 80%, such as at least 85%, such as at least 90%, such as at least 95%, such as at least 99%, such as 100% identity to SEQ ID No. 916, 976, 980, 986, 988, 990, 994, 996, 1010, 1012, 1018, 1020, 1022, 1026, 1028 or 1030, or
b. encoded by a nucleic acid sequence having at least 70%, such as at least 80%, such as at least 85%, such as at least 90%, such as at least 95%, such as at least 99%, such as 100% identity to SEQ ID No. 915, 975, 979, 985, 987, 989, 993, 995, 1009, 1011, 1017, 1019, 1021, 1025, 1027 or 1029 or genomic DNA thereof.

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 14)

The recombinant microbial host cell of any of claims 1 to 11 or claim 14, wherein the ABC transporter comprises Walker A sequences GRPGSGC(S/T) and G(A/S)SGAGKT, linker sequences VSGGERKRVSIA and LNVEQRKRLTIG, and Walker B sequences (F/L)QCWD and LL(V/L)F(L/F)D.

### Claim 16

The recombinant microbial host cell of any preceding claim, further comprising:
a) one or more heterologous CYP demethylases capable of converting thebaine into northebaine, thebaine into oripavine, northebaine into nororipavine and/or oripavine into nororipavine, and one or more demethylase cytochrome P450 reductase (demethylase-CPR), and/or
b) heterologous sequences encoding:
i. a tyrosine hydroxylase (TH) converting L-tyrosine into L-dopa, and
ii. optionally, a TH-CPR capable of reducing the TH of i), and
iii. a L-dopa decarboxylase (DODC) converting L-dopa into dopamine, or a tyrosine decarboxylase (TYDC) converting L-dopa into dopamine, and
iv. a monoamine oxidase converting dopamine into 3,4-DHPAA, or a N-methyl-coclaurine hydroxylase (NMCH) converting (S)-Coclaurine into (S)-3′-hydroxycoclaurine and/or (S)—N-Methylcoclaurine into (S)-3′-Hydroxy-N-Methylcoclaurine; and
v. a norcoclaurine synthase (NCS) converting Dopamine and 4-HPAA into (S)-norcoclaurine and/or 3,4-DHPAA and dopamine to NLDS, and
vi. a 6-O-methyltransferase (6-OMT) converting (S)-norcoclaurine into (S)-Coclaurine and/or norlaudanosoline into (S)-3′-Hydroxy-coclaurine, and
vii. a coclaurine-N-methyltransferase (CNMT) converting (S)-Coclaurine into (S)—N-Methylcoclaurine and/or (S)-3′-hydroxycoclaurine into (S)-3′-hydroxy-N-methyl-coclaurine, and
viii. a 3′-hydroxy-N-methyl-(S)-coclaurine 4′-O-methyltransferase (4′-OMT) converting (S)-3′-Hydroxy-N-Methylcoclaurine into (S)-reticuline, and
ix. a 1,2-dehydroreticuline synthase-1,2-dehydroreticuline reductase (DRS-DRR) converting (S)-reticuline into (R)-reticuline comprised of one or more proteins, and
x. a salutaridine synthase (SAS) converting (R)-reticuline into Salutaridine, and
xi. a salutaridine reductase (SAR) converting Salutaridine to Salutaridinol, and
xii. a salutaridinol 7-O-acetyltransferase (SAT) converting Salutaridinol into 7-O-acetylsalutaridinol, and
xiii. a thebaine synthase (THS) converting 7-O-acetylsalutaridinol or 7-O-acetylsalutaridinol acetate into thebaine;
c) and optionally, one or more glycosyl transferases capable of transferring a glycosyl moiety to a BIA, oripavine or nororipavine.

### Claim 17 (depends on 16)

The recombinant microbial host cell of claim 16, wherein the one or more demethylases is:
a. an N-demethylase comprising a polypeptide sequence having at least 75%, such as at least 85%, such as at least 90% or at least 95% identity to SEQ ID No. 140, 152, 198, 250, 252, 843, or
b. an N-demethylase encoded by a nucleic acid sequence having at least 75%, such as at least 85%, such as at least 90% or at least 95% identity to 141, 153, 199, 251, 253, 844, or genomic DNA thereof, or
c. an O-demethylase comprising a polypeptide sequence having at least 75%, such as at least 85%, such as at least 90% or at least 95% identity to SEQ ID No. 198, 222, 224, 236, or
d. an O-demethylase encoded by a nucleic acid sequence having at least 75%, such as at least 85%, such as at least 90% or at least 95% identity to SEQ ID No. 199, 223, 225, or 237, or genomic DNA thereof.

### Claim 18 (depends on 16, 17)

The recombinant microbial host cell of claim 16 or 17, wherein the one or more CPRs:
a. comprises a polypeptide sequence having 75%, such as at least 85%, such as at least 90% or at least 95% identity to SEQ ID No. 292 or 305, or
b. is encoded by a nucleic acid sequence having at least 75%, such as at least 85%, such as at least 90% or at least 95% identity to SEQ ID No. 293 or 306, or genomic DNA thereof.

### Claim 19

The recombinant microbial host cell of any preceding claim, wherein the one or more glycosyltransferases (UGT) is an aglycone O-UGT or an aglycone O-glucosyltransferase.

### Claim 20

The recombinant microbial host cell of any preceding claim, wherein the one or more glycosyltransferases (UGT):
a. comprises an amino acid sequence having at least 60%, such as at least 70%, such at least 75%, such as at least 80%, such as at least 90%, such as at least 95%, such as at least 99%, such as 100% identity to a UGT comprised in any one of SEQ ID NO: 880, 882, 878, 884, 886, 888, 890, 892, 894, 896, or 898; or
b. is encoded by a nucleic acid sequence having at least 60%, such as at least 70%, such at least 75%, such as at least 80%, such as at least 90%, such as at least 95%, such as at least 99%, such as 100% identity to SEQ ID No. 879, 881, 877, 883, 885, 887, 889, 891, 893, 895 or 897, or genomic DNA thereof.

### Claim 21

The recombinant microbial host cell of any preceding claim, wherein the recombinant microbial host cell is a yeast.

### Claim 22

The recombinant microbial host cell of any preceding claim, wherein the recombinant microbial host cell is Saccharomyces cerevisiae.

### Claim 23

The recombinant microbial host cell of any preceding claim, further comprising an uptake transporter capable of transporting an opioid, such as oripavine, into the recombinant host cell.

### Claim 24 (depends on 23)

The recombinant microbial host cell of claim 23, wherein the uptake transporter is a polypeptide:
a. comprising an amino acid sequence having at least 60%, such as at least 70%, such at least 75%, such as at least 80%, such as at least 90%, such as at least 95%, such as at least 99%, such as 100% identity to an uptake transporter comprised in any one of SEQ ID NO: 307, 311, 317, 461, 473, 733, or 735.
b. encoded by a nucleic acid sequence comprising at least 60%, such as at least 70%, such at least 75%, such as at least 80%, such as at least 90%, such as at least 95%, such as at least 99%, such as 100% identity to 308, 312, 318, 462, 474, 734, 736, or genomic DNA thereof.

### Claim 25

The recombinant microbial host cell of any preceding claim, further comprising an operative biosynthetic pathway capable of producing the thebaine, northebaine, oripavine and/or nororipavine, wherein the pathway comprises one or more polypeptides selected from:
a) a 3-deoxy-D-arabino-2-heptulosonic acid 7-phosphate synthase (DAHP synthase) converting PEP and E4P into DAHP;
b) a 5-enolpyruvylshikimate-3-phosphate (EPSP) synthase (aro1) converting 3-phosphoshikimate and PEP into EPSP;
c) an aro1 polypeptide converting DHAP and PEP into EPSP;
d) a chorismate synthase converting EPSP into Chorismate;
e) a chorismate mutase converting Chorismate into prephenate;
f) a prephenate dehydrogenase (Tyr1) converting prephenate into 4-HPP;
g) an aromatic aminotransferase converting 4-HPP into L-Tyrosine;
h) a tyrosine hydroxylase (TH) converting L-tyrosine into L-dopa
i) a TH-CPR capable of reducing the TH of h);
j) a L-dopa decarboxylase (DODC) converting L-dopa into dopamine;
k) a Tyrosine decarboxylase (TYDC) converting L-dopa into dopamine;
l) a hydroxyphenylpyruvate decarboxylase (HPPDC) converting 4-HPP into 4-HPPA;
m) a monoamine oxidase converting dopamine into 3,4-DHPAA;
n) a norcoclaurine synthase (NCS) converting Dopamine and 4-HPAA into (S)-norcoclaurine;
o) a 6-O-methyltransferase (6-OMT) converting (S)-norcoclaurine into (S)-Coclaurine and/or norlaudanosoline into (S)-3′-Hydroxy-coclaurine;
p) a coclaurine-N-methyltransferase (CNMT) converting (S)-Coclaurine into (S)—N-Methylcoclaurine and/or (S)-3′-hydroxycoclaurine into (S)-3′-hydroxy-N-methyl-coclaurine;
q) a N-methyl-coclaurine hydroxylase (NMCH) converting (S)-Coclaurine into (S)-3′-hydroxycoclaurine and/or (S)—N-Methylcoclaurine into (S)-3′-Hydroxy-N-Methylcoclaurine;
r) a 3′-hydroxy-N-methyl-(S)-coclaurine 4′-O-methyltransferase (4′-OMT) converting (S)-3′-Hydroxy-N-Methylcoclaurine into (S)-reticuline;
s) a 1,2-dehydroreticuline synthase-1,2-dehydroreticuline reductase (DRS-DRR) converting (S)-Reticuline into (R)-reticuline;
t) a salutaridine synthase (SAS) converting (R)-reticuline into Salutaridine;
u) a salutaridine reductase (SAR) converting Salutaridine to Salutaridinol;
v) a salutaridinol 7-O-acetyltransferase (SAT) converting Salutaridinol into 7-O-acetylsalutaridinol;
w) a thebaine synthase (THS) converting 7-O-acetylsalutaridinol or 7-O-acetylsalutaridinol acetate into thebaine;
x) a demethylase converting thebaine into oripavine, thebaine into northebaine, oripavine into nororipavine and/or northebaine into nororipavine; and/or
y) a demethylase-CPR capable of reducing the demethylase of x).

### Claim 26 (depends on 25)

The host cell of the claim 25, wherein the corresponding:
a) DAHP synthase has at least 70% identity to the DAHP synthase comprised in SEQ ID NO: 121;
b) chorismate mutase has at least 70% identity to the chorismate synthase comprised in SEQ ID NO: 123;
c) prephenate dehydrogenase (Tyr1) has at least 70% identity to the DAHP synthase comprised in SEQ ID NO: 125;
d) Tyrosine Hydroxylase (TH) has at least 70% identity to the TH comprised in SEQ ID NO: 127;
e) TH-CPR has at least 70% identity to the TH-CPR comprised in SEQ ID NO: 129;
f) DODC has at least 70% identity to the DODC comprised in SEQ ID NO: 131;
g) Norcoclaurine synthase (NCS) has at least 70% identity to the NCS comprised in SEQ ID NO: 133;
h) 6-OMT has at least 70% identity to the 6-OMT comprised in SEQ ID NO: 135;
i) CNMT has at least 70% identity to the CNMT comprised in SEQ ID NO: 137;
j) NMCH has at least 70% identity to the NMCH comprised in SEQ ID NO: 139;
k) 4′-OMT has at least 70% identity to the 4′-OMT comprised in SEQ ID NO: 141;
l) DRS-DRR has at least 70% identity to the VRS_DDR comprised in SEQ ID NO:143;
m) SAS has at least 70% identity to the SAS comprised in SEQ ID NO: 145;
n) SAT has at least 70% identity to the SAR comprised in SEQ ID NO: 147;
o. SAR has at least 70% identity to the SAT comprised in SEQ ID NO: 149;
p) THS has at least 70% identity to the THS comprised in SEQ ID NO: 151;
q) Demethylase has at least 70% identity to the demethylase comprised in anyone of SEQ ID NO: 153, 155, 157, 256, or 258; and
r) Demethylase-CPR has at least 70% identity to the demethylase-CPR comprised in anyone of SEQ ID NO: 159, 161, or 260.

### Claim 27

A cell culture comprising the recombinant microbial host cell of any preceding claim plus cell growth medium.

### Claim 28 (depends on 27)

A method of producing one or more BIA, BIA-glycoside, oripavine or glycosylated oripavine or glucosylated oripavine, thebaine, northebaine, nororipavine, glycosylated nororipavine or glucosylated nororipavine, comprising:
(a) culturing the cell culture of claim 27 at conditions allowing the cell to produce the BIA; and
(b) optionally recovering and/or isolating the BIA.

### Claim 29 (depends on 28)

The method of claim 28, wherein step (a) comprises culturing in the pH range pH 3 to pH 6.5, such as pH 4 to 6, such as pH 4.5 or pH 5.5, for 5 minutes or longer, such as for 20 minutes or longer, such as for 30 minutes or longer, such as for 40 minutes or longer, such as for 60 minutes or longer, such as for 90 minutes, such as 1 day or longer.

### Claim 30 (depends on 28, 29)

The method of claim 28 or 29, further comprising contacting the nororipavine glycoside or oripavine glycoside with a glycosidase, at conditions allowing the glycosidase to catalyze separation of a glycosyl moiety from the nororipavine glycoside or oripavine glycoside to thereby obtain nororipavine or oripavine.

### Claim 31 (depends on 30)

The method of claim 30, wherein the glycosidase is a β-glycosidase, such as β-glucosidase.

### Claim 32 (depends on 28, 29, 30, 31)

The method of any of claims 28 to 31, wherein the recovered and/or isolated BIA, BIA-glycoside, oripavine or glycosylated oripavine or glucosylated oripavine, thebaine, northebaine, nororipavine, glycosylated nororipavine or glucosylated nororipavine is converted into bis-benzyl nororipavine, nalbuphine, morphine, hydromorphone, codeine, hydrocodone, oxycodone, oxymorphone noroxymorphone, noroxymorphinone, buprenorphine, naloxone, naltrexone, or nalmefene.

### Claim 33 (depends on 27, 28, 29, 30, 31, 32)

Use of the cell culture of claim 27, or the one or more BIA, BIA-glycoside, oripavine or glycosylated oripavine or glucosylated oripavine, thebaine, northebaine, nororipavine or glycosylated nororipavine, glucosylated nororipavine, bis-benzyl nororipavine, nalbuphine, morphine, hydromorphone, codeine, hydrocodone, oxycodone, oxymorphone noroxymorphone, noroxymorphinone, buprenorphine, naloxone, naltrexone, or nalmefene, produced according to the method of any of claims 28 to 32, in the manufacture of a medicament for the relief of pain, opioid use disorder (OUD), opioid overdose, and alcohol use disorder.

### Claim 34 (depends on 33)

The use of the BIA-glycoside of claim 33, wherein the BIA-glycoside is gly-nororipavine or gly-oripavine.

### Claim 35 (depends on 28, 29, 30, 31, 32)

A pharmaceutical composition comprising the one or more BIA, BIA-glycoside, oripavine, thebaine, northebaine, nororipavine or glycosylated nororipavine, glucosylated nororipavine, bis-benzyl nororipavine, nalbuphine, morphine, hydromorphone, codeine, hydrocodone, oxycodone, oxymorphone noroxymorphone, noroxymorphinone, buprenorphine, naloxone, naltrexone, or nalmefene, produced according to the method of any of claims 28 to 32, and one or more agents, additives and/or excipients.

### Claim 36 (depends on 28, 29, 30, 31, 32)

A pharmaceutical composition comprising one or more active pharmaceutical ingredients manufactured from one or more of the BIAs produced according to the method of any of claims 28 to 32, in the manufacture of a medicament for the relief of pain, opioid use disorder (OUD), opioid overdose, and alcohol use disorder.
